Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease

Virology

Volumn 494, Issue , 2016, Pages 215-224

  Hwang, Hye Suk ^a   Lee, Young Tae ^a   Kim, Ki Hye ^a   Park, Soojin ^a   Kwon, Young Man ^a   Lee, Youri ^a   Ko, Eun Ju ^a   Jung, Yu Jin ^a   Lee, Jong Seok ^a,b   Kim, Yu Jin ^a   Lee, Yu Na ^a,c   Kim, Min Chul ^a,c   Cho, Minkyoung ^a   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b National Institute of Biological Resources   (South Korea)

^c Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

Cotton rats; Protection; Respiratory syncytial virus; Safety; Virus like particle

Indexed keywords

DNA VACCINE; FFG VLP; FORMALIN INACTIVATED RESPIRATORY SYNCYTIAL VIRUS VACCINE; HYBRID PROTEIN; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PLASMID DNA; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS LIKE PARTICLE VACCINE; CYTOKINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SECRETING CELL; ARTICLE; CONTROLLED STUDY; COTTON RAT; CYTOKINE RELEASE; DISEASE SEVERITY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; HISTOPATHOLOGY; INFECTION PREVENTION; INFLAMMATORY INFILTRATE; LIMIT OF DETECTION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT ALLERGY; VIRUS ATTACHMENT; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS REPLICATION; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SIGMODONTINAE; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNIZATION; IMMUNOGLOBULIN G; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; VACCINES, DNA; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS;

EID: 84964403188     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2016.04.014     Document Type: Article

References (39)

1. Boukhvalova M.S., Prince G.A., Blanco J.C. The cotton rat model of respiratory viral infections. Biologicals 2009, 37:152-159.
2. Castilow E.M., Olson M.R., Meyerholz D.K., Varga S.M. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J. Virol. 2008, 82:2196-2207.
3. Cherukuri A., Patton K., Gasser R.A., Jr, Zuo F., Woo J., Esser M.T., Tang R.S. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin. Vaccine Immunol. 2013, 20:239-247.
4. Connors M., Collins P.L., Firestone C.Y., Sotnikov A.V., Waitze A., Davis A.R., Hung P.P., Chanock R.M., Murphy B.R. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia - RSV recombinants or RSV. Vaccine 1992, 10:475-484.
5. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 1994, 68:5321-5325.
6. Corvaia N., Tournier P., Nguyen T.N., Haeuw J.F., Power U.F., Binz H., Andreoni C. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. J. Infect. Dis. 1997, 176:560-569.
7. Cullen L.M., Blanco J.C., Morrison T.G. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J. Transl. Med. 2015, 13:350.
8. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., Diaz L., Trento A., Chang H.Y., Mitzner W., Ravetch J., Melero J.A., Irusta P.M., Polack F.P. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 2009, 15:34-41.
9. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 1997, 158:2278-2284.
10. Hotard A.L., Shaikh F.Y., Lee S., Yan D., Teng M.N., Plemper R.K., Crowe J.E., Moore M.L. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 2012, 434:129-136.
11. Hwang H.S., Kwon Y.M., Lee J.S., Yoo S.E., Lee Y.N., Ko E.J., Kim M.C., Cho M.K., Lee Y.T., Jung Y.J., Lee J.Y., Li J.D., Kang S.M. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antivir. Res. 2014, 110:115-123.
12. Hwang H.S., Kwon Y.M., Lee J.S., Yoo S.E., Lee Y.N., Ko E.J., Kim M.C., Cho M.K., Lee Y.T., Jung Y.J., Lee J.Y., Li J.D., Kang S.M. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antivir. Res. 2014, 110C:115-123.
13. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997, 176:1215-1224.
14. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., Parrott R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1969, 89:422-434.
15. Kim K.H., Lee Y.T., Hwang H.S., Kwon Y.M., Kim M.C., Ko E.J., Lee J.S., Lee Y., Kang S.M. Virus-like particle vaccine containing the F protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells. J. Virol. 2015.
16. Ko E.J., Kwon Y.M., Lee J.S., Hwang H.S., Yoo S.E., Lee Y.N., Lee Y.T., Kim M.C., Cho M.K., Lee Y.R., Quan F.S., Song J.M., Lee S., Moore M.L., Kang S.M. Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. Nanomed. Nanotech. Biol. Med. 2015, 11:99-108.
17. Lee J.S., Hwang H.S., Ko E.J., Lee Y.N., Kwon Y.M., Kim M.C., Kang S.M. Immunomodulatory activity of red ginseng against influenza a virus infection. Nutrients 2014, 6:517-529.
18. Lee S., Quan F.S., Kwon Y., Sakamoto K., Kang S.M., Compans R.W., Moore M.L. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antivir. Res. 2014, 111C:129-135.
19. McGinnes L.W., Gravel K.A., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., Schmidt M.R., Morrison T.G. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J. Virol. 2011, 85:366-377.
20. Meyerholz D.K., Griffin M.A., Castilow E.M., Varga S.M. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. Toxicol. Pathol. 2009, 37:249-255.
21. Monick M.M., Powers L.S., Hassan I., Groskreutz D., Yarovinsky T.O., Barrett C.W., Castilow E.M., Tifrea D., Varga S.M., Hunninghake G.W. Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. J. Immunol. 2007, 179:1648-1658.
22. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., Heaton P.M., Fraire A.E., Morrison T.G. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J. Virol. 2010, 84:1110-1123.
23. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8:497-502.
24. Openshaw P.J., Clarke S.L., Record F.M. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 1992, 4:493-500.
25. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 2001, 82:2881-2888.
26. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., Chanock R.M. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J. Virol. 1986, 57:721-728.
27. Quan F.S., Kim Y., Lee S., Yi H., Kang S.M., Bozja J., Moore M.L., Compans R.W. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J. Infec. Dis. 2011, 204:987-995.
28. Quan F.S., Kim Y., Lee S., Yi H., Kang S.M., Bozja J., Moore M.L., Compans R.W. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J. Infect. Dis. 2011, 204:987-995.
29. Raghunandan R., Lu H., Zhou B., Xabier M.G., Massare M.J., Flyer D.C., Fries L.F., Smith G.E., Glenn G.M. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine 2014, 32:6485-6492.
30. Shaw C.A., Galarneau J.R., Bowenkamp K.E., Swanson K.A., Palmer G.A., Palladino G., Markovits J.E., Valiante N.M., Dormitzer P.R., Otten G.R. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease. Vaccine 2013, 31:306-312.
31. Shreiner A.B., Murdock B.J., Sadighi Akha A.A., Falkowski N.R., Christensen P.J., White E.S., Hogaboam C.M., Huffnagle G.B. Repeated exposure to Aspergillus fumigatus conidia results in CD4+T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10. Infect. Immun. 2012, 80:388-397.
32. Siber G.R., Leombruno D., Leszczynski J., McIver J., Bodkin D., Gonin R., Thompson C.M., Walsh E.E., Piedra P.A., Hemming V.G., et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis. 1994, 169:1368-1373.
33. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., Zhou B., Lu H., Boddapati S., Li J., Flyer D., Glenn G. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012, 7:e50852.
34. Srikiatkhachorn A., Braciale T.J. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 1997, 71:678-685.
35. Stokes K.L., Currier M.G., Sakamoto K., Lee S., Collins P.L., Plemper R.K., Moore M.L. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. J. Virol. 2013, 87:10070-10082.
36. Ternette N., Tippler B., Uberla K., Grunwald T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 2007, 25:7271-7279.
37. Tregoning J.S., Yamaguchi Y., Wang B., Mihm D., Harker J.A., Bushell E.S., Zheng M., Liao G., Peltz G., Openshaw P.J. Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J. Immunol. 2010, 185:5384-5391.
38. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev. Med. Virol. 2007, 17:5-34.
39. Varga S.M., Wang X., Welsh R.M., Braciale T.J. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001, 15:637-646.